This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
BIOSCRIP SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against BioScrip Inc.
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until
November 29, 2013 to file lead plaintiff applications in a securities class action lawsuit against BioScrip Inc. (Nasdaq: BIOS), if they purchased the Company’s securities during the period between August 8, 2011 and September 20, 2013, inclusive (the “Class Period”). This action is pending in the Southern District of New York United States District Court.
What You May Do
If you purchased shares of BioScrip and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850, or email KSF Managing Partner Lewis Kahn (
email@example.com) or KSF Partner Melinda Nicholson (
firstname.lastname@example.org). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by
November 29, 2013.
About the Lawsuit
BioScrip and certain of its executives are charged with issuing a series of materially false and misleading statements during the Class Period, violating federal securities laws.
On September 23, 2013, BioScrip disclosed that it received a civil investigative demand from the U.S. Attorney's Office for the Southern District of New York and a subpoena from the New York State Attorney General's Medicaid Fraud Control Unit, regarding the distribution of the product Exjade by the Company's legacy specialty pharmacy division.
Since this news, the price of the Company’s stock has fallen by over 49%—from $11.07 at close of trading the last day of trading before the announcement, September 20, 2013, to $5.65 at close of trading after BioScrip released disappointing third-quarter earnings on November 7, 2013.
About Kahn Swick & Foti, LLC